Literature DB >> 18234696

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.

L K Fisniku1, P A Brex, D R Altmann, K A Miszkiel, C E Benton, R Lanyon, A J Thompson, D H Miller.   

Abstract

Clinically isolated syndromes (CIS), such as optic neuritis, brainstem or spinal cord syndromes are frequently the first clinical presentations of multiple sclerosis. However, not all CIS patients develop multiple sclerosis and in those who do, disability is highly variable. In previous follow-up studies, brain lesions on T2-weighted MRI are associated with increased risk of multiple sclerosis and to an extent disability. We evaluated the longitudinal relationships between the MRI lesions and clinical course over a period of 20 years. CIS patients were recruited between 1984 and 1987 and previously followed up after 1, 5, 10 and 14 years. Of the 140 subjects who were initially recruited with a CIS for a baseline MRI study, we followed up 107 patients after a mean of 20.2 years (range 18-27.7). Multiple sclerosis was diagnosed as clinically definite on clinical grounds only and disability determined using the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC) score. Clinically definite multiple sclerosis developed in 67 out of 107 (63%) overall: 60 out of 73 (82%) with abnormal and 7 out of 34 (21%) with normal baseline MRI. Multiple sclerosis was still relapsing-remitting in 39 (58%)--including 26 (39%) with a 'benign' course (EDSS < or = 3)--whilst 28 (42%) had developed secondary progression. T2 lesion volume at all time-points correlated moderately with 20-year EDSS (r(s) values 0.48 to 0.67; P < 0.001) and MSFC z-score [r(s) values (-0.50) to (-0.61); P < 0.001]. In those developing multiple sclerosis, a concurrent correlation of change in T2 lesion volume with change in EDSS was most evident in years 0-5 (r(s) = 0.69, P < 0.001). The estimated rate of lesion growth over 20 years was 0.80 cm3/year in those who retained a relapsing remitting multiple sclerosis course, and 2.89 cm3/year in those who developed secondary progressive multiple sclerosis, a difference of 2.09 cm3/year (95% CI: 0.77, 2.96; P < 0.001). This study extends previous follow-up of CIS patients and sheds new light on how the lesions evolve according to the natural history. Baseline MRI findings are predictive for development of clinically definite multiple sclerosis. Lesion volume and its change at earlier time points are correlated with disability after 20 years. Lesion volume increases for at least 20 years in relapse-onset multiple sclerosis and the rate of lesion growth is three times higher in those who develop secondary progressive than in those who remain relapsing remitting multiple sclerosis.

Entities:  

Mesh:

Year:  2008        PMID: 18234696     DOI: 10.1093/brain/awm329

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  184 in total

1.  CSF abnormalities can be predicted by VEP and MRI pathology in the examination of optic neuritis.

Authors:  Henrik Horwitz; Matilda Degn; Signe Modvig; Henrik B W Larsson; Benedikte Wanscher; Jette L Frederiksen
Journal:  J Neurol       Date:  2012-06-06       Impact factor: 4.849

2.  In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: a surface-based analysis.

Authors:  J Cohen-Adad; T Benner; D Greve; R P Kinkel; A Radding; B Fischl; B R Rosen; C Mainero
Journal:  Neuroimage       Date:  2011-04-13       Impact factor: 6.556

3.  From injection therapies to natalizumab: views on the treatment of multiple sclerosis.

Authors:  Roberto Bomprezzi; Darin T Okuda; Yazan J Alderazi; Olaf Stüve; Elliot M Frohman
Journal:  Ther Adv Neurol Disord       Date:  2012-03       Impact factor: 6.570

Review 4.  The radiologically isolated syndrome: take action when the unexpected is uncovered?

Authors:  Johann Sellner; Lucas Schirmer; Bernhard Hemmer; Mark Mühlau
Journal:  J Neurol       Date:  2010-05-26       Impact factor: 4.849

Review 5.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 6.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

7.  Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging.

Authors:  Daniel S Reich; Richard White; Irene Cm Cortese; Luisa Vuolo; Colin D Shea; Tassie L Collins; John Petkau
Journal:  Mult Scler       Date:  2015-02-06       Impact factor: 6.312

Review 8.  Optical coherence tomography: a window into the mechanisms of multiple sclerosis.

Authors:  Elliot M Frohman; James G Fujimoto; Teresa C Frohman; Peter A Calabresi; Gary Cutter; Laura J Balcer
Journal:  Nat Clin Pract Neurol       Date:  2008-12

Review 9.  Causes, effects and connectivity changes in MS-related cognitive decline.

Authors:  Carolina de Medeiros Rimkus; Martijn D Steenwijk; Frederik Barkhof
Journal:  Dement Neuropsychol       Date:  2016 Jan-Mar

10.  The incidence of clinically isolated syndrome in a multi-ethnic cohort.

Authors:  Annette Langer-Gould; Sonu M Brara; Brandon E Beaber; Jian L Zhang
Journal:  J Neurol       Date:  2014-04-29       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.